Enjoy complimentary customisation on priority with our Enterprise License!
The global cancer cachexia therapeutics market has the potential to grow by USD 568.85 million during 2019-2023, and the market's growth momentum will accelerate throughout the forecast period.
This report provides a detailed analysis of the market by geography (Asia, Europe, North America, and ROW), and product (progestogens, corticosteroids, combination therapies, and other therapeutics). Also, the report analyzes the market's competitive landscape and offers information on several market vendors, including AbbVie Inc., ANI Pharmaceuticals Inc., Bristol-Myers Squibb Co., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Browse TOC and LoE with selected illustrations and example pages of cancer cachexia therapeutics market
The market is fragmented, and the degree of fragmentation will increase during the forecast period. Vendors are focusing on developing novel therapies for the treatment of cancer cachexia, and on expanding their market reach, established vendors are adopting R&D strategies. AbbVie Inc., ANI Pharmaceuticals Inc., Merck & Co. Inc., and Pfizer Inc. are some of the major market participants. Though the accelerating growth momentum will offer immense growth opportunities, the lack of approved therapies to treat cancer cachexia will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market position, this cancer cachexia therapeutics market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market's competitive landscape and provides information on the products offered by various companies. Moreover, this cancer cachexia therapeutics market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading cancer cachexia therapeutics companies, including:
For more insights on the cancer cachexia therapeutics market share of various regions Request for a FREE sample now!
The increasing number of cancer patients in North America is directly proportional to the number of people with cancer cachexia, and this data indicates promising market opportunities in the region. The high healthcare expenditure in the region is driving the growth of the cancer cachexia therapeutics market.
About 44% of the market's growth will originate from North America during the forecast period. The region is witnessing a high prevalence of cancer and the need for approved drugs, which is inducing several companies to invest in this region. This will subsequently drive the demand for cancer cachexia therapeutics, propelling cancer cachexia therapeutics market growth. The US is the critical market for cancer cachexia therapeutics in North America. Market growth in this region will be faster than the growth of the market in Europe and ROW.
Request for a FREE sample and Get more information on the market contribution of various product segments
The most effective and safest option for the palliative treatment of cancer cachexia are progestogens. Progestogens facilitate weight gain and improve appetite thereby improving the quality of patients with cancer cachexia. This will increase the adoption of progestogens.
However, market growth in this segment will be slower than the growth of the market in the combination therapies segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the cancer cachexia therapeutics market size.
The high prevalence of cancer cachexia provides significant opportunities for market vendors. The large patient cohort requires multiple physician visits and numerous medications for the treatment of cancer cachexia. Asia has a vast cancer patient population, with China, India, and Japan being among the top five countries with the highest incidence of cancer. The high prevalence of cancer cachexia will subsequently drive cancer cachexia therapeutics market growth over the forecast period.
Request for a FREE sample now!
We can help! Our analysts can customize this report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.